CRISPR Gene Editing Market Report 2026

The crispr gene editing market size has grown exponentially in recent years. It will grow from $2.88 billion in 2025 to $3.65 billion in 2026 at a compound annual growth rate (CAGR) of 27.1%. The growth in the historic period can be attributed to need for precise gene modification tools, limitations of earlier gene editing technologies, growth of genomics research, academic adoption, funding for genetic research.

The crispr gene editing market size is expected to see exponential growth in the next few years. It will grow to $8.28 billion in 2030 at a compound annual growth rate (CAGR) of 22.7%. The growth in the forecast period can be attributed to approval of gene editing therapies, expansion of precision medicine, agricultural biotechnology growth, regulatory framework development, technological refinement of crispr systems. Major trends in the forecast period include rising clinical gene therapy research, expansion of agricultural gene editing, growth of functional genomics studies, advancements in delivery technologies, increasing focus on ethical and regulatory compliance.

The growing prevalence of genetic disorders is expected to drive the growth of the CRISPR gene editing market in the coming years. A genetic disorder is a medical condition caused by abnormalities in the genome, including mutations in a single gene (monogenic), multiple genes (polygenic), or chromosomal alterations. The increasing occurrence of genetic disorders is linked to factors such as genetic mutations, aging populations, and consanguineous marriages. CRISPR gene editing plays a significant role in addressing genetic disorders by enabling accurate and targeted modifications to DNA. Researchers use CRISPR technology to identify and correct specific mutations responsible for genetic conditions, restore normal gene function, and reduce disease symptoms, as demonstrated in disorders such as cystic fibrosis and sickle cell anemia. For example, in October 2025, according to the Cystic Fibrosis Trust, a UK-based charity supporting individuals with cystic fibrosis, 164 new cystic fibrosis diagnoses were reported in 2024, with 123 cases detected through newborn screening. By the end of 2024, a total of 11,381 individuals were registered with cystic fibrosis. Therefore, the rising prevalence of genetic disorders is contributing to the growth of the CRISPR gene editing market.

Major companies operating in the CRISPR gene editing market are concentrating on the development of innovative solutions such as gene therapy to expand their customer base, increase sales, and boost revenue. Gene therapy is a medical approach that uses genetic material to treat, prevent, or cure diseases and medical conditions. For instance, in December 2023, the US Food and Drug Administration, a US-based federal agency, approved Casgevy, a cell-based gene therapy, for the treatment of sickle cell disease. Casgevy employs CRISPR/Cas9 genome editing technology, in which hematopoietic stem cells are modified using CRISPR/Cas9 to correct the underlying genetic defect.

In April 2024, Cellistic, a Belgium-based cell therapy platform provider, acquired Artisan Bio for an undisclosed amount. Through this acquisition, Cellistic aims to strengthen its gene and cell therapy development capabilities by integrating Artisan Bio’s STAR-CRISPR Cas-12 gene-editing platform, which enables higher-precision genome modifications and supports advanced engineered cell therapy solutions. Artisan Bio is a US-based biotechnology company focused on developing next-generation CRISPR gene-editing technologies.

Major companies operating in the crispr gene editing market are Crispr Therapeutics, Thermo Fisher Scientific, Intellia Therapeutics, Horizon Discovery, Synthego Corporation, Integrated DNA Technology (Danaher), Editas Medicine, GenScript, Agilent Technologies, New England Biolabs, CSIR-Institute of Genomics & Integrative Biology (IGIB), Strand Life Sciences Pvt. Ltd., Bio Palette Co. Ltd., Churchi Genome Engineering and Therapeutic Research Center, Beam Therapeutics Inc., Eurofins Genomics India, Setsurotech Co. Ltd., Merck Japan, Institut Pasteur, CureVac, Cellectis, BiovelocITA S.r.l., Evotec A.G., SNIPR Biome, Oxford Genetics, ERS Genomics, Alia Therapeutics, Solvo, BioTalentum, BIOCAD, BioVendor, Research & Diagnostic Products, Contipro, Lonza Biotec, Sotio, Selvita, BioVentures Institute Ltd, Sigma-Aldrich, Poseida Therapeutics, NanoCellect Biomedical, Sherlock Biosciences, Repare Therapeutics, Inscripta Inc., Santa Cruz Biotechnology, Caribou Biosciences Inc., Egenesis Inc., Homology Medicines, System Biosciences, Takara Bio USA Inc., Inari Agriculture Inc., Precision BioSciences, Cell Microsystems Inc., GeneCopoeia Inc., Merck KGaA, Origene Technologies Inc., Pluristem Therapeutics Inc.

North America was the largest region in the CRISPR gene editing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the crispr gene editing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the crispr gene editing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the crispr gene editing market by increasing costs of imported reagents, delivery systems, plasmids, and laboratory equipment. Research institutions and biotech firms in North America and Europe are most affected due to dependence on imported inputs, while Asia-Pacific faces higher technology acquisition costs. These tariffs are increasing research and development expenses. However, they are also supporting domestic biotech manufacturing and regional innovation capabilities.

The crispr gene editing market research report is one of a series of new reports that provides crispr gene editing market statistics, including crispr gene editing industry global market size, regional shares, competitors with a crispr gene editing market share, detailed crispr gene editing market segments, market trends and opportunities, and any further data you may need to thrive in the crispr gene editing industry. This crispr gene editing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Clustered regularly interspaced short palindromic repeats (CRISPR) gene editing is an advanced biotechnology technique that enables highly precise modifications to the DNA of living organisms. The technology is based on a natural defense mechanism found in bacteria, in which specific DNA sequences, known as CRISPR, are used to recognize and cut targeted genetic material. CRISPR gene editing allows genes to be added, removed, or altered, making it a powerful tool for research, therapeutic applications, and the potential treatment of genetic disorders.

The main types of CRISPR gene editing include CRISPR-associated nucleases (Cas nucleases), guide ribonucleic acid (RNA), deoxyribonucleic acid (DNA) ligase, restriction endonucleases, and other components. CRISPR-associated nuclease, commonly referred to as Cas nuclease, is a protein that acts as molecular scissors by cutting specific DNA sequences identified by CRISPR. This segment focuses on the development and application of Cas proteins for precise gene editing, with potential uses across industries such as agriculture, medicine, and biotechnology. The market also offers a range of services, including design tools, plasmids and vectors, CRISPR-associated protein 9 (Cas9) and guide RNA, delivery system products, and others. In addition, it encompasses multiple technologies, such as CRISPR/Cas9, zinc finger nucleases, and other gene-editing approaches, which are applied in areas including agriculture, biomedicine, industrial processes, genome engineering, disease modeling, functional genomics, and other applications. These technologies are utilized by various end users, including academic institutions and research centers, biotechnology companies, contract research organizations (CROs), and pharmaceutical and biopharmaceutical companies.

The CRISPR gene editing market includes of revenues earned by entities by providing services such as gRNA design and vector construction, cell line and engineering, screening services, drug development services, and gene therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The CRISPR gene editing market also includes sales of gene editing vectors, laboratory equipment, kits and enzymes, libraries, design tools, antibodies, bioinformatics tools, and cell culture equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.